Released May 5, 2015, after the close
10-Q filed May 6, 2015, 36 days after period end · 0000320017-15-000028
Q1 2014 · 10-Q
Revenue$3.17M$3.17M +78,112.0% vs Q1 2013+60,026.6% vs Q4 2013
Net Income-$19.19K-$19.19K N/M vs Q1 2013N/M vs Q4 2013
EPS Diluted-$0.51-$0.51 N/M vs Q1 2013N/M vs Q4 2013
Operating Income-$18,087,864N/M
Operating Cash Flow-$14,240,267N/M
Free Cash Flowderived-$14,584,797N/M
Margins · derived
Operating margin-570.2%+332244.6 pt vs Q1 2013
Net margin-0.6%+336.7 pt vs Q1 2013
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q1 2014 | Q1 2013 | Q1 2012 | Q1 2011 |
|---|---|---|---|---|
| Revenue | $3.17M | $4.06K | — | $3.77M |
| Net Income | -$19.19K | -$13.68K | -$8.80K | -$9.35M |
| EPS Diluted | -$0.51 | -$0.49 | -$0.53 | -$0.08 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lisata Therapeutics, Inc. · CIK 320017 · Engraved from SEC EDGAR